Preparation and use of kinase inhibitor

A compound of formula I, or a pharmaceutically acceptable salt thereof:

• wherein,
• R1 and R2 can be connected with adjacent N atom to form a ring structure, said ring structure includes a substituted or unsubstituted 3-12 membered saturated or unsaturated heterocycle or a bridged ring or a spiro ring;
• wherein said heterocycle refers to a ring structure containing 0-3 heteroatoms selected from the group consisting of N, O or S, in addition to the nitrogen atom attached to the parent nucleus;
• R3 is selected from a substituted or unsubstituted C1-C8 alkyl, CN, C(O)OR12, CONR13R14, C(O)R15, a substituted or unsubstituted 5-8 membered aryl, a substituted or unsubstituted 5-8 membered heteroaryl, a substituted or unsubstituted 3-12 membered saturated or unsaturated heterocycle or carbocycle;
• wherein said heteroaryl contains 1-3 heteroatoms selected from the group consisting of N, O or S;
• said heterocycle contains 1-3 heteroatoms selected from the group consisting of N, O or S;
• R4 is selected from H, a substituted or unsubstituted C1-C4 alkyl, a substituted or unsubstituted C1-C8 alkoxy, a halogen, OH, CN, C(O)OR12, CONR13R14,C(O)R15, a substituted or unsubstituted 5-8 membered aryl, a substituted or unsubstituted 5-8 membered heteroaryl, a substituted or unsubstituted 3-12 membered saturated or unsaturated heterocycle or carbocycle;
• wherein said heteroaryl contains 1-3 heteroatoms selected from the group consisting of N, O or S;
• said heterocycle contains 1-3 heteroatoms selected from the group consisting of N, O or S;
• R5 is selected from H or C1-C4 alkyl;
• X is CR16;
• A and B are each independently selected from N or CR16;
• Z is N;
• R16 is H, C1-C4 alkyl or C1-C4 haloalkyl;
• L is selected from the group consisting of none, C1-C6 alkylene, C(O), CONR17 or S(O)2;
• Y is H, R18, NR19R20, OH, or Y is selected from part of the group consisting of:
• wherein,
• R6 is none, H, a substituted or unsubstituted C1-C8 alkyl, a substituted or unsubstituted C1-C8 alkoxy, a substituted or unsubstituted C2-C6 acyl, a substituted or unsubstituted C2-C6 sulfonyl, a substituted or unsubstituted C1-C6 alkylenehydroxy, CONR22R23 or C(O)R24;
• R7 may be 0-3 substituents and R7 is a substituted or unsubstituted C1-C8 alkyl, an oxygen or a halogen, or two or more R7 form a bridged cycloalkyl;
• W is CR21, N or O (when W is O, R6 is absent);
• Ya is CR21 or N;
• R21 is H or a halogen;
• R8, R9, R10, R11, R12, R13, R14, R15, R17, R18, R19, R20, R22, R23 and R24 are each independently selected from H, a substituted or unsubstituted C1-C8 alkyl, a substituted or unsubstituted C1-C8 alkoxy, a substituted or unsubstituted C1-C6 alkyleneamino, a substituted or unsubstituted C1-C6 alkylenehydroxy, a substituted or unsubstituted 5-8 membered aryl, a substituted or unsubstituted 5-8 membered heteroaryl, a substituted or unsubstituted 3-12 membered saturated heterocycle or carbocycle;
• wherein said heteroaryl contains at least one heteroatom selected from the group consisting of N, O or S, said heterocycle contains at least one heteroatom selected from the group consisting of N, O or S;
• n and t are 0, 1 or 2, respectively;
• any one of the above mentioned “substituted” means that one or more hydrogen atoms on the group are substituted with substituent(s) selected from the group consisting of a halogen, OH, NH2, CN, an unsubstituted or halogenated C1-C8 alkyl, C1-C8 alkoxy, an unsubstituted or halogenated C2-C6 alkenyl, an unsubstituted or halogenated C2-C6 alkynyl, an unsubstituted or halogenated C2-C6 acyl, an unsubstituted or halogenated 5-8 membered aryl, an unsubstituted or halogenated 5-8 membered heteroaryl, an unsubstituted or halogenated 3-12 membered saturated heterocycle or carbocycle;
• wherein said heteroaryl contains 1-3 heteroatoms selected from the group consisting of N, O or S, said heterocycle contains 1-3 heteroatoms selected from the group consisting of N, O or S.